Observational studyClinical and experimental nephrology2021

Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.

Toshio Mochizuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.